异基因造血干细胞移植后肺移植:泛欧洲经验
本研究纳入1996至2014年间20个欧洲中心因异基因造血干细胞移植后晚发性非感染性肺部并发症接受肺移植的105例患者,并与倾向评分匹配的对照比较。结果显示移植后1、3、5年移植物生存率分别为84%、72%、67%,与对照相当(p=0.75);脓毒症占死亡41%,移植前机械通气为移植物丢失主要风险因素。
要点
- 异基因造血干细胞移植后肺移植的移植物生存与其它终末期疾病相当。
- 脓毒症是主要死因,移植前机械通气为移植物丢失最强风险因素。
- 移植距干细胞移植不足2年增加1年全因死亡风险。
核心结论
- 异基因造血干细胞移植后因晚发性非感染性肺部并发症行肺移植的结局与其它终末期疾病相当。
- 在严格选择的候选者中肺移植可行,未发现移植特异的影响结局因素。
研究设计与样本
- 回顾性多中心队列研究,纳入1996至2014年间20个欧洲中心因干细胞移植后晚发性非感染性肺部并发症行肺移植的105例患者。
- 对照来自Eurotransplant和Scandiatransplant注册的倾向评分匹配人群。
- 采用Kaplan-Meier生存分析和Cox比例风险回归评估移植物丢失预测因素。
主要发现
- 105例患者肺移植后1、3、5年移植物生存率分别为84%、72%、67%,与对照相当(p=0.75)。
- 37例死亡中脓毒症占15例(41%)。
- 移植前机械通气为移植物丢失主要风险因素(HR 6.9,95% CI 1.0-46.7;p<0.001)。
- 4例(4%)出现恶性肿瘤复发。
- 干细胞移植后不足2年行肺移植增加1年全因死亡率(HR 7.5,95% CI 2.3-23.8;p=0.001)。
临床怎么用
- 对异基因造血干细胞移植后晚发性非感染性肺部并发症患者,经常规评估后可考虑肺移植。
- 移植前需评估机械通气状态及距干细胞移植时间,以权衡风险。
局限性
- 研究为回顾性设计,患者经过高度选择,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transplantation (SCT) recipients within 5 years, conferring subsequent 5-year survival of 50%. Lung transplantation is rarely performed in this setting due to concomitant extrapulmonary morbidity, excessive immunosuppression and concerns about recurring malignancy being considered contraindications. This study assesses survival in highly selected patients undergoing lung transplantation for LONIPCs after SCT.SCT patients undergoing lung transplantation at 20 European centres between 1996 and 2014 were included. Clinical data pre- and post-lung transplantation were reviewed. Propensity score-matched controls were generated from the Eurotransplant and Scandiatransplant registries. Kaplan-Meier survival analysis and Cox proportional hazard regression models evaluating predictors of graft loss were performed.Graft survival at 1, 3 and 5 years of 84%, 72% and 67%, respectively, among the 105 SCT patients proved comparable to controls (p=0.75). Sepsis accounted for 15 out of 37 deaths (41%), with prior mechanical ventilation (HR 6.9, 95% CI 1.0-46.7; p<0.001) the leading risk factor. No SCT-specific risk factors were identified. Recurring malignancy occurred in four patients (4%). Lung transplantation <2 years post-SCT increased all-cause 1-year mortality (HR 7.5, 95% CI 2.3-23.8; p=0.001).Lung transplantation outcomes following SCT were comparable to other end-stage diseases. Lung transplantation should be considered feasible in selected candidates. No SCT-specific factors influencing outcome were identified within this carefully selected patient cohort.
引用
- Greer M, Berastegui C, Jaksch P, et al. Lung transplantation after allogeneic stem cell transplantation: a pan-European experience. Eur Respir J. 2018. PMID: 29444913. doi:10.1183/13993003.01330-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。